Acetylcholinesterase inhibitors in the context of therapeutic strategies to combat alzheimer's disease

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 12, 2002, Pages 1853-1865

  Recanatini, Maurizio ^a   Cavalli, Andrea ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alzheimer's disease; Amyloid ; Cholinergic drugs; Cholinergic neurotransmission; Cholinesterase inhibitors; Neurodegeneration

Indexed keywords

AMITRIPTYLINE; BENZAZEPINE DERIVATIVE; BROMOGALANTAMINE; CARBAMIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DICHLORVOS; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; HUPERZINE A; ISOINDOLE DERIVATIVE; METRIFONATE; MILAMELINE; MIRAMELIN; MUSCARINIC AGENT; N (PYRIDYLAMINO)ISOINDOLINE; NICOTINIC AGENT; PHENETHYLAMINE DERIVATIVE; PHYSOSTIGMINE; PIPERIDINE DERIVATIVE; PYRIDOSTIGMINE; RALOXIFENE; RIVASTIGMINE; SELEGILINE; SPIRO(CYCLOPENT[B]INDOLE PIPERIDINE; SYNAPTON; TACRINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELNACRINE;

ALZHEIMER DISEASE; BONE MARROW TOXICITY; CHEMICAL MODIFICATION; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG STRUCTURE; DRUG USE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MUSCLE WEAKNESS; NONHUMAN; PATENT; RETROSPECTIVE STUDY; REVIEW;

EID: 0036930779     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.12.1853     Document Type: Review

References (40)

1. ALZHEIMER A: Ueber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Z Psychiatrie Psychisch-Gerichtlichen Medizin (1907) 64:146-148.
2. SELKOE DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. (2001) 81:741-766.
3. SELKOE DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399:A23-31.
4. HARDY J, SELKOE DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 297:353-356.
5. BARTUS RT, DEAN RL 3rd, BEER B, LIPPA AS: The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217:408-414.
6. BARTUS RT: On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. (2000) 163:495-529.
7. SUMMERS WK, MAJOVSKI LV, MARSH GM, TACHIKI K, KLING A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. (1986) 315:1241-1245.
8. GIACOBINI E, BECKER R, MCILHANY M, KUMAR V: Intracerebroventricular administration of cholinergic drugs: preclinical trials and clinical experience in Alzheimer patients. In: Current research in Alzheimer tberetpy Giacobini E, Becker R (Eds), Taylor & Francis (1988):113-122.
9. MCGLEENON BM, DYNAN KB, PASSMORE AP: Acetylcholinesterase inhibitors in Alzheimer's disease. Br. J. Clin. Pharmacol. (1999) 48:471-480.
10. GAUTHIER S: Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs (1999) 8:1511-1520.
11. GIACOBINI E: Cholinesterase inhibitors: from the Calabar bean to Alzheimer's disease. In: Cholinesterases and cholinesterase inhibitors. Giacobini E (Ed.), Martin Dunitz Ltd (2000):181-226.
12. MOGHUL S,WILKINSON D: Use of acety1cholinesterase inhibitors in Alzheimer's disease. Expert Rev. Neurotherapeutics (2001) 1:61-69.
13. BENZI G, MORETTI A: Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur. J. Pharmacol. (1998) 346:1-13.
14. FROLICH L: The cholinergic pathology in Alzheimer's disease - discrepancies between clinical experience and pathophysiological findings. J. Neural. Transm. (2002) 109:1003-1013.
15. DAVIS KL, MOHS RC, MARIN D et al.: Cholinergic markers in elderly patients with early signs of Alzheimer disease. Jama (1999) 281:1401-1406.
16. DEKOSKY ST, IKONOMOVIC MD, STYREN SD et al.: Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. (2002) 51:145-155.
17. SOREQ H, SEIDMAN S: Acetylcholinesterase-new roles for an old actor. Nat. Rev. Neurosci. (2001) 2:294-302.
18. GRISARU D, STERNFELD M, ELDOR A, GLICK D, SOREQ H: Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem. (1999) 264:672-686.
19. JOHNSON G, MOORE SW. The adhesion function on acetylcholinesterase is located at the peripheral anionic site. Biochem. Biophys. Res. Commun. (1999) 258:758-762.
20. DE FERRARI GV, CANALES MA, SHIN I, WEINER LM, SILMAN I, INESTROSA NC: A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry (2001) 40:10447-10457.
21. YU Q, HOLLOWAY HW, UTSUKI T, BROSSI A, GREIG NH: Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J. Med. Chem. (1999) 42:1855-1861.
22. YU Q, HOLLOWAY HW, FLIPPEN-ANDERSON JL, HOFFMAN B, BROSSI A, GREIG NH: Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J. Med. Chem. (2001) 44:4062-4071.
23. GIACOBINI E, SPIEGEL R, ENZ A, VEROFF AE, CUTLER NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J. Neural. Transm. (2002) 109:1053-1065.
24. BRUFANI M, CASTELLANO C, MARTA M et al.: A long-lasting cholinesterase inhibitor affecting neural and behavioral processes. Pharmacol. Biochem. Behav. (1987) 26:625-629.
25. MIDDLETON E Jr, KANDASWAMI C, THEOHARIDES TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. (2000) 52:673-751.
26. KRYGER G, SILMAN I, SUSSMAN JL: Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J. Physiol. Paris (1998) 92:191-194.
27. ELLMAN GL, COURTNEY KD, ANDRES V, FEATHERSTONE RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., (1961) 7:88-95.
28. DORAISWAMY PM, STEFFENS DC: Combination therapy for early Alzheimer's disease: what are we waiting for? J. Am. Geriatr. Soc. (1998) 46:1322-1324.
29. BUTTERFIELD DA, DRAKE J, POCERNICH C, CASTEGNA A: Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol. Med. (2001) 7:548-554.
30. MCGEER PL, SCHULZER M, MCGEER EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 47:425432.
31. MCGEER PL: Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging (2000) 17:1-11.
32. ENDOH M, KUNISHITA T, TABIRA T: No effect of anti-leprosy drugs in the prevention of Alzheimer's disease and β-amyloid neurotoxicity. J. Neurol. Sci. (1999) 165:28-30.
33. WISE PM: Estrogens and neuroprotection. Trends Endocrinol. Metab. (2002) 13:229-230.
34. EIKELENBOOM P, ZHAN SS, VAN GOOL WA, ALLSOP D: Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. (1994) 15:447-450.
35. SCHUBERT P, RUDOLPHI K: Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Alzheimer Dis. Assoc. Disord. (1998) 12(Suppl.2):S21-28.
36. FERRONI S, MARCHINI C, OGATA T, SCHUBERT P: Recovery of deficient cholinergic calcium signaling by adenosine in cultured rat cortical astrocytes. J. Neurosci. Res. (2002) 68:615-621.
37. FOURNIER J, STEINBERG R, GAUTHIER T et al.: Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience (1993) 55:629-641.
38. PAULSEN O, MOSER EI: A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. Trends Neurosci. (1998) 21:273-278.
39. A receptor. J. Neurosci. (2002) 22:5572-5580.
40. MELCHIORRE C, ANDRISANO V, BOLOGNESI ML et al.: Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J. Med. Chem. (1998) 41:4186-4189.